Quarterly ResultMay 8, 2026, 08:03 AM
Alamar Biosciences Q1 Revenue +99% to $26.0M; IPO Raises $197.8M Net
AI Summary
Alamar Biosciences reported strong financial results for Q1 2026, with total revenue nearly doubling to $26.0 million, a 99% increase year-over-year. The company also launched two new products in neurodegenerative disease research. Following the quarter end, Alamar Biosciences completed its initial public offering in April 2026, raising $197.8 million in net proceeds, significantly strengthening its balance sheet. Despite revenue growth, the company reported an increased net loss of $21.3 million, partly due to a loss on remeasurement of convertible notes.
Key Highlights
- Q1 2026 total revenue was $26.0 million, a 99% increase from $13.1 million year-over-year.
- Initial Public Offering in April 2026 raised $197.8 million in net proceeds.
- Consumable revenue grew 178% to $14.0 million, from $5.0 million in Q1 2025.
- Instrument revenue grew 78% to $7.4 million, from $4.1 million in Q1 2025.
- Gross margin improved to 56% in Q1 2026, up from 49% in Q1 2025.
- Net loss for Q1 2026 was $21.3 million, compared to $7.7 million in Q1 2025.
- Cash, cash equivalents, and restricted cash were $69.5 million as of March 31, 2026.
- Operating expenses increased 79% to $26.8 million in Q1 2026.